Identifying the link between defective SOD activity and clinical characteristics in IPAH patients is important, which, in turn, can be used as an epigenetic biomarker for a new and improved therapeutic strategy. The gene discussed is SOD1; the disease is idiopathic pulmonary arterial hypertension.